痛風病気治療の世界市場

痛風病気治療の世界市場は2030年までに40億米ドルに達する見込み

2024年に27億米ドルと推定される痛風病気治療の世界市場は、2024年から2030年にかけてCAGR 6.7%で成長し、2030年には40億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである非ステロイド性抗炎症薬は、CAGR 7.0%を記録し、分析期間終了時には18億米ドルに達すると予想されます。副腎皮質ステロイド薬セグメントの成長率は、分析期間中CAGR 5.0%と推定されます。

米国市場は7億4,200万米ドルと推定、中国はCAGR 10.5％で成長予測

米国の痛風病気治療市場は、2024年に7億4,200万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8億3,310万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.3％と6.6％と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界の痛風病気治療市場- 主要動向と促進要因まとめ

痛風が慢性疾患管理における最優先課題として浮上している理由

痛風は、関節内の過剰な尿酸の結晶化によって引き起こされる炎症性関節炎の一種であり、世界的に有病率が増加している深刻な慢性疾患として認知されつつあります。痛風は、肥満、高血圧、腎臓病などの代謝性疾患と関連することが多く、もはや散発的な、あるいは生活習慣に関連した病気ではなく、より広範な全身性の炎症性疾患や心血管疾患のリスクの一部であると考えられています。痛風は主に40歳以上の男性と閉経後の女性に発症し、高齢化、座りがちな生活、プリン体を多く含む加工食品の摂取増加により、その発症率は増加しています。

このような認識の変化により、急性期のフレイル管理と長期的な尿酸コントロールの両方に対する臨床上の関心が高まっています。従来の治療法には、急性症状に対しては非ステロイド性抗炎症薬（NSAIDs）、コルチコステロイド、コルヒチンなどがあり、慢性的な尿酸降下療法にはアロプリノールやフェブキソスタットなどのキサンチンオキシダーゼ阻害薬があります。しかしながら、最適な病勢コントロール、治療不遵守、および関連する併存疾患により、より忍容性が高く、より効果的な治療選択肢に対するアンメットニーズが浮き彫りになっています。痛風は、持続的な介入を必要とする長期的な代謝疾患として管理されるようになってきており、治療戦略や研究の優先順位が再構築されつつあります。

新たな治療法と薬剤クラス別は治療パラダイムをどのように変えているのか？

痛風の治療状況は、従来の薬剤の限界を克服するためにデザインされた新規治療薬の導入により進化しています。最も重要な技術革新は、ペグロチターゼのようなウリカーゼベースの生物学的製剤であり、これは尿酸を酵素的に分解し、治療抵抗性または上顎痛風の症例に特に有効です。これらの薬剤は、標準的な経口薬に反応しない重症の慢性患者にのみ使用され、迅速な尿酸クリアランスにおけるその有効性から、先進医療における重要なツールとして位置づけられています。しかし、免疫原性や輸液関連反応の管理には課題が残っており、ペグインターフェロン、徐放性製剤、配合製剤などのさらなる研究が必要です。

フェブキソスタットのような選択的非プリン型キサンチンオキシダーゼ阻害剤は、アロプリノールに不耐容の患者にとって、薬物動態がより予測しやすく、腎機能障害時の用量調節が少ない代替薬となります。開発中の新薬は、尿酸塩の溶解性を改善したり、腎尿細管での再吸収を阻害したり（URAT1阻害薬など）、より包括的な尿酸塩コントロールを実現するためにメカニズムを組み合わせたりすることを目的としています。さらに、痛風領域では精密医療が台頭しており、薬理遺伝学的ツールにより、より安全で効果的な投与が導かれつつある-特にアロプリノール過敏症症候群に罹患しやすい集団に関連する-。このような開発により、痛風治療が近代化されつつあり、個々のリスクプロファイルに合わせた、より的を絞った、忍容性の高い、有効な解決策が提供されつつあります。

診断、アクセス、治療の最適化に影響を与える動向とは？

世界の痛風治療市場は、早期診断、患者のアドヒアランス、医療システムの関与に対する進化したアプローチによって形成されています。重要な動向の1つは、尿酸塩結晶の沈着を特定するためにデュアルエネルギーCTスキャンや超音波検査の利用が増加していることであり、これにより、症状が再燃する前であっても、より早期かつ正確な診断が可能となっています。これにより、尿酸値を下げるための積極的な戦略をより早く開始できるようになり、治療成績が向上しています。一方、プライマリ・ケア提供者の間では、治療が不十分な痛風の長期的リスクに対する認識が高まっており、維持療法や定期的な血清尿酸モニタリングの利用が拡大しています。

患者関与の面では、デジタルヘルスツールや遠隔医療プラットフォームが、服薬アドヒアランス、食事管理、症状追跡をサポートするために利用されています。これらのツールは、長期的な疾患教育や生活習慣の改善を必要とする慢性痛風患者にとって特に有用です。製薬会社はまた、レジメンを簡素化し、脱落率を減らすために、合剤と1日1回投与の経口療法にますます注力しています。新興市場においては、手頃な価格の尿酸降下薬ジェネリック医薬品へのアクセスの改善と診断インフラの拡充が重要な動向です。政策レベルでは、痛風が非感染性疾患プログラムに徐々に組み込まれつつあり、特に心血管系や腎臓の合併症の負担と重複する地域ではその傾向が顕著です。

世界の痛風病気治療市場の成長を牽引するものは何か？

痛風病気治療市場の成長は、疾病疫学、治療イノベーション、医療システムの進化に直接結びついた、相互に関連するいくつかの要因によって牽引されています。メタボリックシンドロームと肥満の世界の負担増は、特に高齢化社会と都市化経済において痛風の発生率を著しく高めています。これにより、急性および慢性治療オプションの対象人口が拡大しています。同時に、痛風は断続的な不便さではなく、重篤な慢性疾患であるという認識が広まり、早期介入と長期投薬が促進され、尿酸降下療法の需要が高まっています。

生物学的製剤、ウリカーゼ治療薬、デュアルメカニズム治療薬の革新は、管理が困難な患者や難治性の患者に対する治療の選択肢を広げています。次世代痛風治療薬のパイプラインは、安全性プロファイルの改善や患者中心の投与レジメンとともに、より広範な採用と治療期間の延長を促しています。規制当局の支援、希少疾病用医薬品の指定、および新しい治療法を裏付ける現実世界のエビデンスは、市場参入と保険会社による保険適用を加速させています。最後に、デジタルヘルスの統合、診断能力の向上、新興国市場における医療アクセスの拡大が世界市場の勢いを強めており、痛風治療が慢性疾患管理ポートフォリオにおける優先事項として位置づけられています。

セグメント

薬剤クラス（非ステロイド性抗炎症薬、副腎皮質ステロイド薬、コルヒチン、尿酸降下薬、その他の薬剤クラス）;疾患タイプ（急性痛風、慢性痛風）;投与経路（経口、非経口）;流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の44社）

• Addex Therapeutics
• Allena Pharmaceuticals
• Amgen Inc.
• Arthrosi Therapeutics
• AstraZeneca plc
• BioCryst Pharmaceuticals, Inc.
• GlaxoSmithKline plc
• Horizon Therapeutics plc
• Ionis Pharmaceuticals, Inc.
• JW Pharmaceutical Corporation
• LG Chem
• Menarini Group
• Merck & Co., Inc.
• Novartis AG
• Polaris Group
• Regeneron Pharmaceuticals, Inc.
• Selecta Biosciences
• Simcere Pharmaceutical Group
• Takeda Pharmaceutical Company Ltd.
• Teijin Pharma Limited

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Gout Disease Treatment Market to Reach US$4.0 Billion by 2030

The global market for Gout Disease Treatment estimated at US$2.7 Billion in the year 2024, is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$742.0 Million While China is Forecast to Grow at 10.5% CAGR

The Gout Disease Treatment market in the U.S. is estimated at US$742.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$833.1 Million by the year 2030 trailing a CAGR of 10.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Gout Disease Treatment Market - Key Trends & Drivers Summarized

Why Is Gout Emerging as a High-Priority Focus in Chronic Disease Management?

Gout, a form of inflammatory arthritis caused by excess uric acid crystallization in the joints, is gaining recognition as a serious chronic condition with growing global prevalence. Often linked to metabolic disorders such as obesity, hypertension, and kidney disease, gout is no longer considered a sporadic or lifestyle-related illness but part of a broader spectrum of systemic inflammatory and cardiovascular risks. The disease predominantly affects men over 40 and postmenopausal women, and its incidence is rising due to aging populations, sedentary lifestyles, and increased consumption of purine-rich and processed foods.

This shift in perception has intensified clinical attention toward both acute flare management and long-term uric acid control. Conventional treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine for acute episodes, and xanthine oxidase inhibitors such as allopurinol and febuxostat for chronic urate-lowering therapy. However, suboptimal disease control, treatment non-compliance, and associated comorbidities have highlighted the unmet need for better-tolerated, more effective therapeutic options. Gout is increasingly being managed as a long-term metabolic disorder requiring sustained intervention, which is reshaping therapeutic strategies and research priorities.

How Are Emerging Therapies and Drug Classes Transforming Treatment Paradigms?

The treatment landscape for gout is evolving with the introduction of novel therapies designed to overcome the limitations of traditional drugs. Among the most significant innovations are uricase-based biologics such as pegloticase, which enzymatically degrade uric acid and are particularly effective in treatment-refractory or tophaceous gout cases. These drugs are reserved for severe, chronic patients who fail to respond to standard oral medications, and their efficacy in rapid urate clearance has positioned them as critical tools in advanced care. However, challenges remain in managing immunogenicity and infusion-related reactions, prompting further research into pegylated, extended-release, or combination formulations.

Selective non-purine xanthine oxidase inhibitors, such as febuxostat, offer alternatives for patients intolerant to allopurinol, with more predictable pharmacokinetics and fewer dose adjustments in renal impairment. New agents in development aim to improve urate solubility, inhibit reabsorption in renal tubules (e.g., URAT1 inhibitors), or combine mechanisms to deliver more comprehensive urate control. Moreover, precision medicine is emerging in the gout field, with pharmacogenetic tools guiding safer and more effective dosing-particularly relevant in populations susceptible to allopurinol hypersensitivity syndrome. These developments are modernizing gout therapy by offering more targeted, tolerable, and efficacious solutions tailored to individual risk profiles.

What Trends Are Influencing Diagnosis, Access, and Treatment Optimization?

The global gout treatment market is being shaped by evolving approaches to early diagnosis, patient adherence, and health system engagement. One significant trend is the increased use of dual-energy CT scans and ultrasound in identifying urate crystal deposits, enabling earlier and more accurate diagnosis even before symptomatic flares. This is improving treatment outcomes by allowing proactive urate-lowering strategies to begin sooner. Meanwhile, growing awareness among primary care providers about the long-term risks of undertreated gout is leading to greater use of maintenance therapy and regular serum uric acid monitoring.

On the patient engagement front, digital health tools and telemedicine platforms are being used to support medication adherence, dietary management, and symptom tracking. These tools are especially useful for chronic gout sufferers requiring long-term disease education and lifestyle modification. Pharmaceutical companies are also increasingly focusing on fixed-dose combinations and once-daily oral therapies to simplify regimens and reduce drop-off rates. In emerging markets, improving access to affordable urate-lowering generics and expanding diagnostic infrastructure are crucial trends. At the policy level, gout is gradually being included in non-communicable disease programs, particularly in regions where it overlaps with cardiovascular and renal comorbidity burdens.

What Is Driving Growth in the Global Gout Disease Treatment Market?

The growth in the gout disease treatment market is driven by several interconnected factors directly tied to disease epidemiology, therapeutic innovation, and health system evolution. The rising global burden of metabolic syndrome and obesity is significantly increasing the incidence of gout, especially in aging populations and urbanizing economies. This is expanding the target population for both acute and chronic treatment options. At the same time, greater awareness of gout as a serious chronic illness rather than an intermittent inconvenience is fostering earlier intervention and long-term medication use, boosting demand for urate-lowering therapies.

Innovations in biologics, uricase therapies, and dual-mechanism drugs are expanding treatment options for patients with difficult-to-manage or refractory disease. The pipeline of next-generation gout drugs, alongside improved safety profiles and patient-centric dosing regimens, is encouraging broader adoption and longer treatment durations. Regulatory support, orphan drug designations, and real-world evidence backing newer therapies are accelerating their market entry and coverage by insurers. Lastly, digital health integration, improved diagnostic capabilities, and increased healthcare access in developing markets are reinforcing global market momentum, positioning gout treatment as a rising priority in chronic disease management portfolios.

SCOPE OF STUDY:

The report analyzes the Gout Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, Other Drug Classes); Disease Type (Acute Gout, Chronic Gout); Administration Route (Oral, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Addex Therapeutics
• Allena Pharmaceuticals
• Amgen Inc.
• Arthrosi Therapeutics
• AstraZeneca plc
• BioCryst Pharmaceuticals, Inc.
• GlaxoSmithKline plc
• Horizon Therapeutics plc
• Ionis Pharmaceuticals, Inc.
• JW Pharmaceutical Corporation
• LG Chem
• Menarini Group
• Merck & Co., Inc.
• Novartis AG
• Polaris Group
• Regeneron Pharmaceuticals, Inc.
• Selecta Biosciences
• Simcere Pharmaceutical Group
• Takeda Pharmaceutical Company Ltd.
• Teijin Pharma Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Gout Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Prevalence of Hyperuricemia and Gout Propels Long-Term Demand for Chronic Disease Therapies
  • Aging Population and Lifestyle-Linked Risk Factors Fuel Growth of Gout Drug Prescription Rates
  • Increased Use of Urate-Lowering Therapies (ULTs) Strengthens Market for Allopurinol and Febuxostat Formulations
  • Growing Demand for Targeted Anti-Inflammatory Agents Spurs Development of IL-1 Inhibitors and Biologics
  • Pipeline Innovation in Xanthine Oxidase Inhibitors and Uricosurics Expands Therapeutic Options for Refractory Gout
  • Expansion of Comorbidity-Linked Gout Cases Supports Demand for Safer, Cardiovascular-Compatible Drug Profiles
  • Improved Diagnostic Awareness and Early Screening Campaigns Boost Market Access in Primary Care Settings
  • Adoption of Personalized Medicine Approaches Encourages Pharmacogenomic-Based Gout Management
  • Real-World Evidence Supporting Long-Term Use of ULTs Enhances Physician Confidence and Patient Adherence
  • Increased Awareness of Untreated Gout Complications Fuels Patient Demand for Proactive Treatment Regimens
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gout Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gout Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gout Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gout Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Colchicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Colchicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Colchicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Urate-Lowering Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Urate-Lowering Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Urate-Lowering Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Acute Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Acute Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Acute Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Chronic Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Chronic Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Chronic Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• JAPAN
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• CHINA
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• EUROPE
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Gout Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Gout Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Gout Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• FRANCE
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• GERMANY
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 140: UK Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Gout Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Gout Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Gout Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• INDIA
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 215: India Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Gout Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Gout Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Gout Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Gout Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Gout Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Gout Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• AFRICA
  • Gout Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Gout Disease Treatment by Drug Class - NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Gout Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Gout Disease Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Gout Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Gout Disease Treatment by Disease Type - Acute Gout and Chronic Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Gout Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Acute Gout and Chronic Gout for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Gout Disease Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Gout Disease Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Gout Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030

IV. COMPETITION